Natalizumab (Tysabri)

American Journal of Neuroradiology

Volumn 31, Issue 9, 2010, Pages 1588-1590

  Selewski, David T ^a   Shah, G V ^b   Segal, B M ^c   Rajdev, P A ^c   Mukherji, S K ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; NATALIZUMAB; VASCULAR CELL ADHESION MOLECULE 1;

ANTIBODY PRODUCTION; BLOOD TRANSFUSION REACTION; BURKHOLDERIA INFECTION; CROHN DISEASE; CRYPTOSPORIDIOSIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG BINDING; DRUG COST; DRUG HYPERSENSITIVITY; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; HUMAN; LEUKOCYTE ADHERENCE; LIVER TOXICITY; MELANOMA; MULTIPLE SCLEROSIS; MYCOBACTERIUM AVIUM; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; REVIEW; SIDE EFFECT; TREATMENT INDICATION; VIRUS ENCEPHALITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; CELL ADHESION; CELL MIGRATION INHIBITION; HUMANS; LEUKOCYTES; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS;

EID: 77958567394     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A2226     Document Type: Review

References (19)

1. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23
2. Polman CH, O'Connor PW, Havrdova, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
3. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-74
4. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32
5. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-25
6. Department of Health and Human Services. Tysabri risk minimization action plan: summary of TOUCH. http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM107197.pdf. Accessed June 28, 2010
7. Lobb RR, Hemler ME. The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest 1994;94:1722-28
8. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992;356:63-66
9. Brocke S, Piercy C, Steinman L, et al. Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc Natl Acad Sci U S A 1999;96:6896-901 (Pubitemid 29274981)
10. Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005;64:1336-42
11. Ley K, Laudanna C, Cybulsky MI, et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007;7:678-89 (Pubitemid 47327397)
12. Goodin DS, Cohen BA, O'Connor P, et al. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;71:766-73
13. Rudick RA, Sandrock A. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 2004;4:571-80 (Pubitemid 38890585)
14. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23
15. Clifford DB, DeLuca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9:438-46
16. Bezabeh S, Flowers CM, Kortepeter C, et al. Review article: clinically significant liver injury in patients treated with natalizumab (TYSABRI). Aliment Pharmacol Ther 2010;31:1028-35. Epub 2010 Feb 16
17. Center for Drug Evaluation and Research (CDER). Tysabri (Natalizumab) biologic license application 125104/15. In: Proceedings of the Peripheral and Central Nervous System Drugs Advisory Committee, Gaithersburg, Maryland. March 7-8, 2006; available at http://www.fda.gov/ohrms/dockets/ac/06/slides/2006- 4208S1-Slide-Index.htm. Accessed June 28, 2010
18. Ismail A, Kemp J, Sharrack B. Melanoma complicating treatment with natalizumab (Tysabri) for multiple sclerosis. J Neurol 2009;256:1771-72. Epub 2009 Jul 16
19. Mullen JT, Vartanian TK, Atkins MB. Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 2008;358:647-48